William G Herrington
Overview
Explore the profile of William G Herrington including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1916
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Herrington W, Haynes R
N Engl J Med
. 2024 Jul;
391(2):178-179.
PMID: 38986062
No abstract available.
12.
Mayne K, Sardell R, Staplin N, Judge P, Zhu D, Sammons E, et al.
Clin J Am Soc Nephrol
. 2024 Jul;
PMID: 38949880
Background: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are recommended treatment for adults with chronic kidney disease (CKD), but uncertainty exists regarding their use in patients with frailty and/or multimorbidity, among whom polypharmacy...
13.
Nangaku M, Herrington W, Goto S, Maruyama S, Kashihara N, Ueki K, et al.
Clin Exp Nephrol
. 2024 Apr;
28(6):588-595.
PMID: 38643286
Background: EMPA-KIDNEY assessed the effects of empagliflozin 10 mg once daily vs. placebo in 6609 patients with chronic kidney disease (CKD) at risk of progression, including 612 participants from Japan....
14.
Fletcher R, Herrington W, Agarwal R, Mayne K, Arnott C, Jardine M, et al.
Clin J Am Soc Nephrol
. 2024 Apr;
PMID: 38622766
Clinical Trial registry name and registration number: ClinicalTrials.gov Identifiers: NCT02065791 (CREDENCE), NCT03036150 (DAPA-CKD), NCT03594110 (EMPA-KIDNEY).
15.
Patel S, Kang Y, Im K, Neuen B, Anker S, Bhatt D, et al.
Circulation
. 2024 Apr;
149(23):1789-1801.
PMID: 38583093
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear. Methods: This was...
16.
Mayne K, Staplin N, Keane D, Wanner C, Brenner S, Cejka V, et al.
J Am Soc Nephrol
. 2023 Dec;
35(2):202-215.
PMID: 38082486
Significance Statement: SGLT2 inhibitors reduce risk of kidney progression, AKI, and cardiovascular disease, but the mechanisms of benefit are incompletely understood. Bioimpedance spectroscopy can estimate body water and fat mass....
17.
Roddick A, Wonnacott A, Webb D, Watt A, Watson M, Staplin N, et al.
BMC Nephrol
. 2023 Oct;
24(1):310.
PMID: 37880609
Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney...
18.
Grams M, Coresh J, Matsushita K, Ballew S, Sang Y, Surapaneni A, et al.
JAMA
. 2023 Oct;
330(13):1266-1277.
PMID: 37787795
Importance: Chronic kidney disease (low estimated glomerular filtration rate [eGFR] or albuminuria) affects approximately 14% of adults in the US. Objective: To evaluate associations of lower eGFR based on creatinine...
19.
Mayne K, Preiss D, Herrington W
Br J Cardiol
. 2023 Sep;
30(1):3.
PMID: 37705832
No abstract available.
20.
Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan R, Antunes M, et al.
Eur Heart J
. 2023 Aug;
44(39):4043-4140.
PMID: 37622663
No abstract available.